StreetInsider.com News Articles

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

CAMBRIDGE, Mass., Sept. 04, 2026 (GLOBE NEWSWIRE) -- Apnimed, Inc. (Nasdaq: APMD) (“Apnimed” or the “Company”), a late stage clinical pharmaceutical company dedicated to the discovery, development and commercialization of novel oral therapies that address the neurobiology of sleep-related breathing diseases, today announced that on August 31, 2026, the compensation committee of Apnimed’s board of directors granted 10 new non-executive employees non-qualified stock options to purchase an aggregate of 428,428 shares of the Company’s common stock under Apnimed’s 2026 Inducement Plan (the “Plan”). Each stock option granted has an exercise price per share of $26.85, which is

Apnimed, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Fri, 04 Sep 2026 16:01:00 -0400

Cantor Fitzgerald Starts Apnimed Inc. (APMD) at Overweight

Tue, 25 Aug 2026 07:32:01 -0400

(Updated - August 25, 2026 7:32 AM EDT)

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed Inc. (NASDAQ: APMD) with a Overweight rating and a price target of $60.00.

The analyst comments "We are initiating coverage of APMD with an Outperform rating and $60 PT representing ~2x upside from the current ~$32/share. Our PT is based on a DCF of FCF through 2033, with a 15% discount rate to reflect regulatory and commercial risk, and a standard terminal growth rate of 3%. ● The company is developing Oxnimbi, a combo pill comprised of aryoxybutinin (antimuscarinic) and atomoxetine (aka Straterra, a norepi

Cantor Fitzgerald Starts Apnimed Inc. (APMD) at Overweight

Tue, 25 Aug 2026 07:32:01 -0400

(Updated - August 25, 2026 7:32 AM EDT)

Cantor Fitzgerald analyst Josh Schimmer initiates coverage on Apnimed Inc. (NASDAQ: APMD) with a Overweight rating and a price target of $60.00.

LifeSci Capital Starts Apnimed Inc. (APMD) at Outperform

Tue, 25 Aug 2026 06:29:04 -0400

LifeSci Capital initiates coverage on Apnimed Inc. (NASDAQ: APMD) with a Outperform rating and a price target of $50.00.

For an analyst ratings summary and ratings history on Apnimed Inc. click here. For more ratings news on Apnimed Inc. click here.

Shares of Apnimed Inc. closed at $25.63 yesterday.

BofA Securities Starts Apnimed Inc (APMD) at Buy

Tue, 25 Aug 2026 06:09:27 -0400

(Updated - August 25, 2026 6:09 AM EDT)

BofA Securities analyst Jason Gerberry initiates coverage on Apnimed Inc (NASDAQ: APMD) with a Buy rating and a price target of $41.00.

The analyst comments "We initiate coverage of Apnimed with a Buy rating and $41 PO, based on a risk-adjusted DCF of sole asset Oxnimbi (AD109), an oral therapy for obstructive sleep apnea (OSA) with a February 28, 2027 PDUFA date. Our thesis rests on three factors: 1) a differentiated mechanism targeting the neuromuscular dysfunction underlying OSA versus PAP and obesity-directed GLP-1s; 2) positive Phase 3 data, including 34-44% AHI reductions, supporting a

BofA Securities Starts Apnimed Inc (APMD) at Buy

Tue, 25 Aug 2026 06:09:27 -0400

(Updated - August 25, 2026 6:09 AM EDT)

BofA Securities analyst Jason Gerberry initiates coverage on Apnimed Inc (NASDAQ: APMD) with a Buy rating and a price target of $41.00.

Evercore ISI Starts Apnimed Inc. (APMD) at Outperform

Tue, 25 Aug 2026 06:03:32 -0400

Evercore ISI analyst Umer Raffat initiates coverage on Apnimed Inc. (NASDAQ: APMD) with a Outperform rating.

For an analyst ratings summary and ratings history on click here. For more ratings news on click here.

Shares of closed at $25.63 yesterday.

Form SCHEDULE 13G Apnimed, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 07 Aug 2026 15:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26890538.html

Form SCHEDULE 13G Apnimed, Inc. Filed by: AMERIPRISE FINANCIAL INC

Fri, 07 Aug 2026 15:05:00 -0400

si-local-file:///var/storage/secattach/20260807/26890538.html

Form SCHEDULE 13G Apnimed, Inc. Filed by: Tao Capital Management LP

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884275.html

Form SCHEDULE 13G Apnimed, Inc. Filed by: Tao Capital Management LP

Thu, 06 Aug 2026 16:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26884275.html

Form 4 Apnimed, Inc. For: Aug 03 Filed by: Morningside Venture Investments Ltd

Wed, 05 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26874714.html

Form 4 Apnimed, Inc. For: Aug 03 Filed by: Morningside Venture Investments Ltd

Wed, 05 Aug 2026 16:19:00 -0400

si-local-file:///var/storage/secattach/20260805/26874714.html

Form 4 Apnimed, Inc. For: Aug 03 Filed by: Chimera Investment LLC

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874287.html

Form 4 Apnimed, Inc. For: Aug 03 Filed by: Chimera Investment LLC

Wed, 05 Aug 2026 16:11:00 -0400

si-local-file:///var/storage/secattach/20260805/26874287.html

Apnimed raises $220.8M in upsized Nasdaq IPO